Alle Storys
Folgen
Keine Story von Helsinn Healthcare SA mehr verpassen.

Helsinn Healthcare SA

Helsinn and Biovitrum enter a license agreement for nordic marketing of ALOXI®, a drug that prevents nausea and vomiting in cancer patients

Lugano, Switzerland and Stockholm, Sweden (ots)

HELSINN
HEALTHCARE SA, a Swiss pharmaceutical group, and BIOVITRUM AB, a
Swedish Biotechnology company, announce the signing of an agreement
granting BIOVITRUM the exclusive License and Distribution rights of
Aloxi® (Palonosetron hydrochloride) in the NORDIC TERRITORY.
Aloxi® is a strong and long-lasting antiemetic belonging to the
second generation of serotonin (5-HT3) antagonists, the leading class
for the prevention of nausea and vomiting induced by chemotherapy.
Aloxi" showed a great efficacy during the acute and delayed phase
after chemotherapy treatment as compared to other first generation
5-HT3. The product is already commercialised in the US, where over
three million uses have been completed successfully. Aloxi® is
currently on the market in some European countries, as well as in
several countries of Latin America where the tradename is Onicit®.
There is still a medical need for a better prevention of Nausea and
Vomiting due to chemotherapy treatments. In 2004 the US National
Comprehensive Cancer Network (NCCN) guidelines indicated Aloxi® as
the treatment of choice for the prevention of acute and delayed
nausea and vomiting due to moderately emetogenic chemotherapies.
"We are delighted to sign this new agreement with BIOVITRUM and
look forward to initiating a successful co-operation for Aloxi® in
the Nordic territory", said Dr. Riccardo Braglia, Managing Director
of HELSINN HEALTHCARE SA. "We are pleased that the patients and the
medical community in this region will enjoy the benefits of an
innovative antiemetic like Aloxi®".
"We are pleased to enter this agreement with Helsinn and to be the
partner company to launch Aloxi® in the Nordic countries", said Mats
Pettersson, CEO of BIOVITRUM. "Not only does our product portfolio
already contain medicine against adverse effects of chemotherapeutics
but we are also very active in the field of 5-HT receptor active
compounds in our R&D operations. Aloxi® thus fits our business
development strategy very well and we are committed to make Aloxi® a
success".
About Chemotherapy-Induced Nausea and Vomiting (CINV)
CINV is estimated to affect 85% of cancer patients undergoing
chemotherapy and can result in a delay or discontinuation of
chemotherapy treatments. The supportive care area is becoming of
paramount importance to help patients deal with adverse events of
anticancer therapies. With good supportive care drugs, cancer
patients are able to tolerate the anti-cancer treatment to a greater
extent, improving their chances of completing their treatment course
successfully with a better quality of life.
About Aloxi®
Aloxi(r) is a selective 5-HT3-receptor antagonist, developed for
the prevention of CINV, with a long half-life of 40 hours and at
least 30 times higher receptor binding affinity than currently
available compounds. Since its availability in USA in September 2003,
there are over 3 million successful uses of Aloxi®. The product
showed to be effective in preventing both acute and delayed CINV in
patients receiving emetogenic chemotherapies. For more information
about this product please visit our website: www.palonosetron.net and
www.aloxi.com.
About HELSINN HEALTHCARE
HELSINN HEALTHCARE SA is a privately owned pharmaceutical group
with headquarters in Switzerland and is the worldwide licensor of
Aloxi®. HELSINN's core business is the licensing of pharmaceuticals
in niche therapeutic areas. The company's business strategy is to
in-license early-stage new chemical entities and complete their
development from the performance of pre-clinical/clinical studies and
CMC development to the attainment of market approvals in strategic
markets (U.S. and Europe). HELSINN's products are eventually
out-licensed to its marketing partners for distribution. The active
pharmaceutical ingredients and the finished dosage forms are
manufactured at HELSINN's cGMP facilities and supplied worldwide to
its customers. For more information about HELSINN, please visit
www.helsinn.com.
About BIOVITRUM AB
Biovitrum is one of the larger biopharma companies in Europe. With
operations in Sweden and in the UK Biovitrum conducts research and
develops pharmaceuticals for both broad diseases and conditions that
affect smaller patient populations. Biovitrum focuses on drugs for
the treatment of obesity, diabetes, inflammation and blood diseases
as well as a number of well defined niche indications. Biovitrum
develops and produces protein-based drugs on a contractual basis and
markets a range of specialist pharmaceuticals primarily in the Nordic
countries. Biovitrum has approximately 500 employees. For more
information see www.biovitrum.com/.
Contact person HELSINN
Rachid BenHamza, Ph.D., Head Business Unit Oncology & Supportive
Care.
Tel:    +41/91/985'21'21
E-Mail:  info-hhc@helsinn.com
Contact person BIOVITRUM AB
Mats Pettersson, CEO
Phone:  +46/8/697'20'00
Mobile: +46/70/314'75'79
E-Mail:  mats.pettersson@biovitrum.com
Anna Karin Källén, Head of Communications
Phone:    +46/8/697'20'85
Mobile:   +46/73/433'20'85
Internet:  annakarin.kallen@biovitrum.com
Paul de Potocki, Senior VP Commercial & Strategic Development
Phone:  +46/8/697'28'49
Mobile: +46/70/669'96'18
E-Mail:  paul.de.potocki@biovitrum.com

Weitere Storys: Helsinn Healthcare SA
Weitere Storys: Helsinn Healthcare SA
  • 08.02.2006 – 08:00

    HELSINN and THERABEL PHARMA announce a license agreement for Aloxi®

    Lugano (ots) - HELSINN HEALTHCARE SA signed an Agreement with THERABEL PHARMA under which it granted THERABEL PHARMA the exclusive License and Distribution rights to distribute, market and sell Aloxi® (palonosetron hydrochloride) in France, Belgium, Luxemburg and The Netherlands. Aloxi® is a strong and long-lasting antiemetic belonging to ...

  • 22.06.2005 – 08:00

    Helsinn and Angelini announce a license agreement for ALOXI® in Portugal

    Lugano, Switzerland and Lisboa, Portugal (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ANGELINI FARMACÊUTICA, a Portuguese Pharmaceutical company, announce the signing of an agreement granting ANGELINI the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in PORTUGAL. ALOXI® is a strong and long acting ...

  • 13.06.2005 – 12:00

    Exelixis and Helsinn sing agreement for XL119 (Becatecarin)

    South San Francisco, Calif and Lugano, Switzerland (ots) - Exelixis, Inc. (Nasdaq: EXEL) and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition, Helsinn will assume the cost of the Phase III program going forward. In return, Exelixis ...